On Dec 8, 2018 Acelrx Pharmaceuticals Inc (NASDAQ:ACRX) Shorts Increased By 1.48%

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Corporate Logo

Big Money Sentiment increased to 1.22 in 2018 Q2. It has change of 0.15, from 2018Q1’s 1.07. The ratio is positive due to AcelRx Pharmaceuticals, Inc. positioning: 7 sold and 11 reduced. 9 funds acquired stakes and 13 increased stakes. Investors holded 4.27 million in 2018Q1 but now own 4.49 million shares or 5.17% more.
Bridgeway Management owns 246,150 shs. Gsa Capital Ptnrs Ltd Liability Partnership invested in 0.01% or 53,658 shs. Bank & Trust Of New York Mellon reported 44,003 shs. Wells Fargo & Co Mn, a California-based fund reported 31,003 shs. Blackrock invested in 0% or 673,115 shs. The United Kingdom-based Barclays Public Ltd Com has invested 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). 53,853 are owned by Granite Invest Ptnrs Ltd Limited Liability Company. Meeder Asset stated it has 1,300 shs or 0% of all its holdings. Manufacturers Life The has 0% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 362 shs. Susquehanna Intl Gru Llp invested 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). 13,781 are owned by Jpmorgan Chase &. Morgan Stanley invested 0% in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Vanguard Grp Incorporated invested in 1.65M shs. Invesco Limited holds 0% or 12,865 shs. Deutsche Bank & Trust Ag reported 18,076 shs.

AcelRx Pharmaceuticals, Inc. had 3 selling transactions and 3 insider buys since September 24, 2018. This’s net activity of $75,982. On Tuesday, November 13 ASADORIAN RAFFI bought $15,646 worth of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) or 5,000 shs. Shares for $141,755 were sold by Dasu Badri N on Monday, October 15. $31,289 worth of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) was sold by Hamel Lawrence G. $49,120 worth of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) was bought by Palmer Pamela P on Monday, November 19.

It was showed an increase on Acelrx Pharmaceuticals Inc (NASDAQ:ACRX)’s shares shorted with 1.48%. In December was issued ACRX’s total 3.25M shares shorted by FINRA. That’s 1.48% up from 3.21 million shares. Acelrx Pharmaceuticals Inc (NASDAQ:ACRX) has 469,100 shares average volume. It’ll cost 7 days for ACRX to recover its previous position.

Ticker’s shares touched $3.36 during the last trading session after 3.07% change.AcelRx Pharmaceuticals, Inc. has volume of 1.61M shares. Since December 8, 2017 ACRX has risen 1.54% and is uptrending. ACRX underperformed by 14.08% the S&P500.

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain.The firm is valued at $256.68 million. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet, which is in Phase III clinical trial for the treatment of moderate-to-severe acute pain.Last it reported negative earnings. The companyÂ’s late-stage investigational product candidate is Zalviso, a pre-programmed and patient-controlled analgesia device that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain.

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Ratings Coverage

Total analysts of 5 have positions in AcelRx Pharmaceuticals (NASDAQ:ACRX) as follows: 4 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 80%. Since June 12, 2018 according to StockzIntelligence Inc AcelRx Pharmaceuticals has 6 analyst reports. The company rating was maintained by Ladenburg Thalmann on Wednesday, October 10. The company rating was upgraded by Jefferies on Monday, October 15.

For more AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) news released briefly go to: Seekingalpha.com, Seekingalpha.com, Nasdaq.com, Seekingalpha.com or Seekingalpha.com. The titles are as follows: “Akers Biosciences leads Healthcare gainers; Sonoma Pharmaceuticals leads the losers – Seeking Alpha” released on November 19, 2018, “Hopes Are High For AcelRx After Dsuvia Approval – Will Price Follow? – Seeking Alpha” on November 05, 2018, “Pre-Market Most Active for Nov 9, 2018 : GE, ACRX, FNSR, AMD, QQQ, AR, YELP, SQQQ, HSBC, BABA, AAPL, ACB – Nasdaq” with a publish date: November 09, 2018, “AcelRx Finally Has An AdCom Date. Time For A Run Up? – Seeking Alpha” and the last “AcelRx Will Overcome Its Recent Stock Woes – Seeking Alpha” with publication date: October 18, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.